Tuberc Respir Dis.  2007 Oct;63(4):362-367.

Pulmonary Thromboembolism after Post-menopause Hormonal Replacement Therapy

• Kim SY
• Park JH
• Lee HK
• Lee HP
• Lee HK
• Choi SJ
• Yum HK

Abstract

Hormonal replacement therapy (HRT) has been proven for treatment of postmenopausal symptoms such as hot flushes, night sweats and urologic symptoms. HRT became very popular in the 1990's, when there were several reports showing that it also helped with other menopausal complications such as osteoporosis and cardiovascular disease. Recent studies report that the incidence of breast cancer, endometrial cancer, cerebral infarction, coronary artery diseases, deep vein thrombosis and pulmonary thrombembolism could rise after HRT. Among these side effects of HRT, the risk of pulmonary thromboembolism increases 2 to 4 fold after HRT, but can vary with the use of different doses and preparations. Here, we summarize the risk factors and clinical courses for 5 patients who developed pulmonary thromboembolism after postmenopausal HRT.

Keyword

Postmenopause hormone replacement therapy(HRT); Pulmonary thromboembolism; Deep vein thrombosis

MeSH Terms

Breast Neoplasms
Cardiovascular Diseases
Cerebral Infarction
Coronary Artery Disease
Endometrial Neoplasms
Female
Humans
Incidence
Osteoporosis
Postmenopause*
Pulmonary Embolism*
Risk Factors
Sweat
Venous Thrombosis

Figure

• 

  Figure 1 Chest X-ray on admission. Left costophrenic angle obliteration is revealed due to left pleural effusion (A). Wedge shaped ill-defined inhomogenous density is revealed at minor fissure and pleural surface of right upper lung (B).

• 

  Figure 2 Computed tomographic angiography. Multifocal thromboembolism are revealed at mainly segmetal and subsegmental arterial branches supplying both lower lobes (A). Multifocal thromboembolism are revealed at lobar and segmental branches supplying both whole lungs except right middle lobe (B).

• 

  Figure 3 Lower Extrimity Doppler. Deep vein thrombosis are revealed at left popliteal and most proximal superficial femoral vein (A). Deep vein thrombosis are revealed from left common iliac to common femoral vein (B).

Reference

1. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet. 1996. 348:977–980.

2. Douketis JD, Julian JA, Kearon C, Anderson DR, Crowther MA, Bates SM, et al. Does the type of hormone replacement therapy influence the risk of deep vein thrombosis? A prospective case-control study. J Thromb Haemost. 2005. 3:943–948.

3. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy. JAMA. 2002. 288:872–881.

4. Bae SJ, Kim JS, Kim JH, Yun YJ, Lee SA. A case of venous thrombosis developed in a woman taking oral contraceptives with antithrombin III, protein C and protein S deficiencies. Korean J Obstet Gynecol. 2006. 49:1383–1388.

5. Scarabin PY, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet. 2003. 362:428–432.

6. Barlow DH. Hormone replacement therapy and the risk of deep vein thrombosis. Int J Gynecol Obstet. 1997. 59:S29–S33.

7. Wu O. Postmenopausal hormone replacement therapy and venous thromboembolism. Gender Medicine. 2005. 2:S18–S27.

8. Lidegaard O, Edstrim B, Kreiner S. Oral contraceptives and venous thromboembolism. A case-control study. Contraception. 1998. 57:291–301.

9. Vessay M, Mant D, Smith A, Yeates D. Oral contraceptives and venous thromboembolism: findings in a large prospective study. Br Med J. 1986. 292:526.

10. Gerstman BB, Piper JM, Freiman JP, Tomita DK, Kennedy DL, Ferguson WJ, et al. Oral contraceptive estrogen and progestin potencies and the incidence of deep venous thromboembolism. Int J Epidemiol. 1990. 19:931–936.

11. Gerstman BB, Piper JM, Tomita DK, Ferguson WJ, Stadel BV, Lundin FE. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol. 1991. 133:32–37.

12. Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet. 1996. 348:981–983.